Please login to the form below
RA
This page shows the latest RA news and features for those working in and with pharma, biotech and healthcare.
Galapagos expands presence in fibrosis, NASH with Evotec deal
The company based in Mechelen, Belgium looks set to break into the big time this year, thanks to its JAK 1 selective inhibitor filgotinib, a new RA treatment co-developed with
Latest news
-
Gilead awaits CEO and readouts to revive fortunes
NASH and oral RA drugs set for crucial readouts. Gilead saw its revenues and profits decline steeply in 2018, with the arrival of generic competition in HIV in Europe adding to
-
Orchard surpasses IPO expectations, raising $200m
This financing round was led by Deerfield Management, with other investments pouring in from the likes of RA Capital Management and Venrock.
-
Gilead and Galapagos JAK contender scores in RA trial
drugs to help patients with active RA who don’t respond adequately to current biologics. ... blocker Humira (adalimumab) in RA when it comes to clinical responses gauged by doctors and patients.
-
Gilead, Galapagos JAK inhibitor clears phase II test
The drug is also in development for rheumatoid arthritis (RA), ulcerative colitis and Crohn’s disease with phase III trials already underway in those indications and results due in the coming ... Humira (adalimumab) in RA when it comes to clinical
-
Daily Brief: Orchard raises $150m, Astellas swoops for early-stage gene company, Amicus gets FDA Fabry approval
The financing was led by Deerfield Management, with significant new investments from a host of other investors, including RA Capital Management, Venrock, Foresite Capital and Perceptive Advisors.
More from news
Approximately 8 fully matching, plus 142 partially matching documents found.
Latest Intelligence
-
Drug launches to watch in 2019
The good news for the company is that it has not one but two potential blockbusters likely to gain approval in 2019: Upadacitinib (AbbVie) for RA and risankizumab (co-marketed with ... Likewise, upadacitinib will face competition in both RA and atopic
-
Deal Watch January 2018
Royalty monetisation. 230. Jiangsu Hengrui Medicine/Arcutis. SHR0302, selective JAK inhibitor, for dermatology disorders (currently p2 for RA in China).
-
European CTR implementation advances ethical assessment of clinical trials
Timelines are becoming stricter with regard to the fact that compatibility with Regulatory Authority (RA) assessment must be ensured. ... Per the 2001/20/EC directive, assessment was independent from RA and this rule has created more flexibility for EC
-
Behavioural design - it's a no-brainer
Let's start with rheumatoid arthritis. Fatal medication errors relating to a disease-modifying medication for RA prompted an investigation into patient behaviour.
-
Deal Watch December 2015
Galapagos (NL). Gilead. Collaboration. licence. JAK1-selective inhibitor, filgotinib in phase II for RA and Crohn's disease .
More from intelligence
Approximately 0 fully matching, plus 22 partially matching documents found.
Latest from PMHub
-
More tell, less sell: HCP-centric comms
Burlington, MA: 2017. 11. DeJong C, Aguilar T, Tseng CW, Lin GA, Boscard in WJ, Dudley RA.
-
Love Your Heart: An Innovative Interactive Video Programme
It’s astonishing how many people with RA don't know that their condition could be detrimental to their heart. ... understand the reasons why RA increases CVD risk. understand the reasons why RA increases CVD risk.
-
THE OTHER SIDE OF … RHEUMATOID ARTHRITIS
“I harassed my GP enough to get it caught early”. Meet Georgie. At age 26, Georgie was diagnosed with rheumatoid arthritis, an autoimmune inflammatory condition that affects up to 1% of the population worldwide. Suffering from such incredible
-
Behavioural design - it's a no-brainer
Let's start with rheumatoid arthritis. Fatal medication errors relating to a disease-modifying medication for RA prompted an investigation into patient behaviour.
-
Biosimilars: Bringing patients into the conversation
Published in eyeforpharma January 2017 by Mariel Metcalfe. In a recent white paper, we explored the impact that biosimilars are having and likely to have on the rising cost of RA
More from PMHub
Approximately 1 fully matching, plus 18 partially matching documents found.
Featured jobs
-
Account Director, Medical Education
-
Salary TBC
-
Project Manager/ Account Manager
-
Salary TBC
-
Senior Medical Writer
-
Great salary and benefits
- Editorial Assistant Medical Education Agency
-
£25, 000 - £26, 000
-
Senior Medical Writer
-
Salary TBC
-
Senior Medical Writer
-
Up to £50, 000 with Benefits
- Account Manager, Medical Communications and Marketing
-
£30, 000 – £40, 000 benefits and bonus
-
Digital Account Director
-
Salary TBC
Subscribe to our email news alerts
- Lighthouse Medical Commuications US appoints Lisa Druce as its new Managing Partner
- GW Pharma's cannabis-based medicine to be tested in dementia
- International Childhood Cancer Day 2019
- AZ says dropping MedImmune will help ‘streamline’ its R&D
- Merck puts prostate cancer firmly in Keytruda’s sights
- Biosimilar Herceptin helps Roche gain new Perjeta recommendation
PMHub
Cello Health
Cello Health’s mission is to help our clients unlock the potential that exists with their assets, brands and organisations in...
Latest intelligence
- International Childhood Cancer Day 2019
- The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
- Immuno-oncology in 2019: the rapid evolution continues
- Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
- Mixing up Focus Groups
- A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...
Quick links
Infographics
